Close

What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Additionally, the College of American Pathologists (CAP)  has stated: “CAP applauds and supports the objectives, processes and work completed as of December 2018 by the Clinical Pharmacogenetics Implementation Consortium (CPIC®). These efforts will help clinicians, laboratories, health care providers and vendors.”

CPIC resources are freely available under a Creative Commons public domain license.
Read the license page for more details.

Team

Leader
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Leader
Teri E. Klein, Ph.D.
Stanford University

Director
Kelly Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital, Memphis

CPIC Informatics Co-Directors
Michelle Whirl-Carrillo, Ph.D.
Stanford University

James M. Hoffman, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Stanford CPIC Coordinator
Michelle Whirl-Carrillo, Ph.D.
Stanford University

Steering Committee

Mary V. Relling, Pharm.D. St. Jude Children’s Research Hospital, Memphis

Teri E. Klein, Ph.D. Stanford University

Julie A. Johnson, Pharm.D. University of Florida

Dan M. Roden, M.D. Vanderbilt University

Rachel F. Tyndale, Ph.D. University of Toronto and CAMH

Scientific Advisory Board

Gwendolyn A. McMillin, Ph.D. ARUP Laboratories

Robert Nussbaum, M.D. University of California, San Francisco

Heidi Rehm, Ph.D. Partners Healthcare

Marc S. Williams, M.D. Geisinger

Sandy Aronson, Partners Personalized Medicine

Justin B. Starren, M.D., Ph.D., Northwestern University

  • CYP2C19 testing may assist with prescribing sertraline and escitalopram April 16, 2019
    Mary Relling (St. Jude Children's Research Hospital) and I (Teri Klein) as Co-Principal Investigators of the Clinical Pharmacogenetics Implementation Consortium (CPIC) have been discussing the letter that the FDA recently sent to a genomics laboratory expressing concern that “providers may make inappropriate treatment decisions based” on pharmacogenetic testing offered by that lab. The FDA specifically […]
  • New CPIC Guideline: CYP2D6 and atomoxetine March 5, 2019
    The CPIC Guideline for atomoxetine and CYP2D6 is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB page for atomoxetine, and the CPIC website.Atomoxetine is a non-stimulant medication used in the treatment of attention-deficit/hyperactivity disorder. Atomoxetine is metabolized by CYP2D6 and  genetic variation effects atomoxetine pharmacokinetics. Atomoxetine exposure is […]
  • New CPIC guideline: potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes December 11, 2018
    The CPIC Guidelines for potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB pages for RYR1 and CACNA1S, and the CPIC website. Potent volatile anesthetic agents are used for inducing general anesthesia.  Malignant hyperthermia susceptibility can lead to life-threatening reactions to these agents or the depolarizing muscle relaxant succinylcholine.The CPIC guideline and supplement summarize evidence from […]
  • CYP2D6*14A and *14B are updated to *114 and *14 based on the current PharmVar release November 19, 2018
    PharmGKB and CPIC revised the CYP2D6 allele names *14A and *14B to be in concordance with the latest major PharmVar release. CYP2D6*14A is revised to *114 and *14B to *14 in the variant and clinical annotations. The allele choices in the annotation of the CPIC guidelines for CYP2D6 have been updated to reflect the change.The Gene-specific Information […]
  • PharmGKB data used to establish a minimum genetic testing panel for psychiatry October 26, 2018
    The lack of standardization of which genes or alleles should be included in pharmacogenetic testing panels is a major barrier to the full implementation of pharmacogenomics in the clinic. In an effort to help clinicians select an appropriate pharmacogenetic test, Dr. Chad Bousman and Dr. Abdullah Al Maruf of the University of Calgary and Dr. […]